<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00314912</url>
  </required_header>
  <id_info>
    <org_study_id>CL-758017</org_study_id>
    <nct_id>NCT00314912</nct_id>
  </id_info>
  <brief_title>Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease</brief_title>
  <official_title>An Open-Label Extension of the Phase III Study CL-758007 With Tramiprosate (3APS) in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellus Health Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellus Health Inc</source>
  <brief_summary>
    <textblock>
      The purpose of this Phase III open-label extension study is to evaluate the long-term safety
      of Tramiprosate (3APS) in patients with mild to moderate Alzheimerâ€™s disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duration of treatment: 12 months. Patients who complete the Phase III clinical trial will be
      offered the opportunity to receive Tramiprosate (3APS) in an open-label extension study
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2006</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the long-term safety of Tramiprosate (3APS).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To provide additional long-term data on the efficacy of Tramiprosate (3APS).</measure>
  </secondary_outcome>
  <enrollment>650</enrollment>
  <condition>Alzheimer's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramiprosate (3APS)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have successfully completed the full 78-week duration of the
             double-blind CL-758007 study.

          -  Male or female (age 50 years and older): Female must be of non-childbearing potential
             (i.e. surgically sterilized or at least 2 years post-menopausal).

          -  Patient must be living in the community with a reliable caregiver. Participant living
             in an assisted living facility may be included if study medication intake is
             supervised and participant has a reliable caregiver.

          -  The patient must be presenting a reasonably good nutritional status.

          -  Signed inform consent from the patient or legal representative.

        Exclusion Criteria:

        Patients will not be eligible to participate in the study if they meet any of the following
        criteria:

          -  The patient participates in another drug trial during the study.

          -  The patient with a clinically significant and/or uncontrolled condition or other
             significant medical disease.

          -  The patient is unable to swallow medication tablets.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>San Francisco Clinical Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2006</study_first_submitted>
  <study_first_submitted_qc>April 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2006</study_first_posted>
  <last_update_submitted>July 13, 2007</last_update_submitted>
  <last_update_submitted_qc>July 13, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tramiprosate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

